Share on StockTwits

Aratana Therapeutics (NASDAQ:PETX) Insider Linda Rhodes sold 10,000 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $16.00, for a total value of $160,000.00. Following the transaction, the insider now directly owns 446,305 shares of the company’s stock, valued at approximately $7,140,880. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on PETX shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Friday, June 6th. They now have a $23.00 price target on the stock, down previously from $25.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Wednesday, May 14th. They now have a $22.00 price target on the stock, down previously from $30.00. Finally, analysts at Zacks downgraded shares of Aratana Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, April 14th. They now have a $18.40 price target on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Aratana Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $28.40.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 3.71% during mid-day trading on Thursday, hitting $17.90. 141,110 shares of the company’s stock traded hands. Aratana Therapeutics has a one year low of $8.07 and a one year high of $29.32. The stock has a 50-day moving average of $14.23 and a 200-day moving average of $17.13. The company’s market cap is $514.8 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.09 million. The company’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts predict that Aratana Therapeutics will post $-1.51 earnings per share for the current fiscal year.

Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.